Replies to post #76672 on Biotech Values

[DewDiligence]

If adding INF to INFORM resulted in 99% SVR, patients would be all over it.

Naturally. As a practical matter, however, HCV companies are aiming for an 80% SVR rate in genotype-1 patients. If they can achieve 80% or more without interferon, they are unlikely to add interferon back into the mix to try to push SVR even higher.